These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21559452)

  • 1. Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression.
    Zhang L; Bhasin M; Schor-Bardach R; Wang X; Collins MP; Panka D; Putheti P; Signoretti S; Alsop DC; Libermann T; Atkins MB; Mier JW; Goldberg SN; Bhatt RS
    PLoS One; 2011 Apr; 6(4):e19144. PubMed ID: 21559452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.
    Wang X; Zhang L; Goldberg SN; Bhasin M; Brown V; Alsop DC; Signoretti S; Mier JW; Atkins MB; Bhatt RS
    J Transl Med; 2011 Dec; 9():220. PubMed ID: 22188900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?
    Schor-Bardach R; Alsop DC; Pedrosa I; Solazzo SA; Wang X; Marquis RP; Atkins MB; Regan M; Signoretti S; Lenkinski RE; Goldberg SN
    Radiology; 2009 Jun; 251(3):731-42. PubMed ID: 19474376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.
    Chang YS; Adnane J; Trail PA; Levy J; Henderson A; Xue D; Bortolon E; Ichetovkin M; Chen C; McNabola A; Wilkie D; Carter CA; Taylor IC; Lynch M; Wilhelm S
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):561-74. PubMed ID: 17160391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy.
    Tang TC; Man S; Xu P; Francia G; Hashimoto K; Emmenegger U; Kerbel RS
    Neoplasia; 2010 Nov; 12(11):928-40. PubMed ID: 21076618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.
    Alfaro C; Suarez N; Gonzalez A; Solano S; Erro L; Dubrot J; Palazon A; Hervas-Stubbs S; Gurpide A; Lopez-Picazo JM; Grande-Pulido E; Melero I; Perez-Gracia JL
    Br J Cancer; 2009 Apr; 100(7):1111-9. PubMed ID: 19277038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice.
    Hakimé A; Hines-Peralta A; Peddi H; Atkins MB; Sukhatme VP; Signoretti S; Regan M; Goldberg SN
    Radiology; 2007 Aug; 244(2):464-70. PubMed ID: 17641366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma.
    Murakami M; Zhao S; Zhao Y; Chowdhury NF; Yu W; Nishijima K; Takiguchi M; Tamaki N; Kuge Y
    Int J Oncol; 2012 Nov; 41(5):1593-600. PubMed ID: 22965141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma.
    Vatsyayan R; Singhal J; Nagaprashantha LD; Awasthi S; Singhal SS
    Mol Carcinog; 2013 Jan; 52(1):39-48. PubMed ID: 22006587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines.
    Tochizawa S; Masumori N; Yanai Y; Ohmoto Y; Yabuuchi Y; Tsukamoto T
    Biomed Res; 2008 Dec; 29(6):271-8. PubMed ID: 19129670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ubenimex attenuates acquired sorafenib resistance in renal cell carcinoma by inhibiting Akt signaling in a lipophagy associated mechanism.
    Liu S; Gao M; Wang X; Ding S; Lv J; Gao D; Wang Z; Niu Z
    Oncotarget; 2016 Nov; 7(48):79141-79153. PubMed ID: 27816967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib.
    Roulin D; Waselle L; Dormond-Meuwly A; Dufour M; Demartines N; Dormond O
    Mol Cancer; 2011 Jul; 10():90. PubMed ID: 21791089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.
    Kim S; Yazici YD; Calzada G; Wang ZY; Younes MN; Jasser SA; El-Naggar AK; Myers JN
    Mol Cancer Ther; 2007 Jun; 6(6):1785-92. PubMed ID: 17575107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model.
    Kususda Y; Miyake H; Gleave ME; Fujisawa M
    Br J Cancer; 2012 Jun; 106(12):1945-52. PubMed ID: 22588555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.
    Heng DY; Mackenzie MJ; Vaishampayan UN; Bjarnason GA; Knox JJ; Tan MH; Wood L; Wang Y; Kollmannsberger C; North S; Donskov F; Rini BI; Choueiri TK
    Ann Oncol; 2012 Jun; 23(6):1549-55. PubMed ID: 22056973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
    Shimizu S; Takehara T; Hikita H; Kodama T; Tsunematsu H; Miyagi T; Hosui A; Ishida H; Tatsumi T; Kanto T; Hiramatsu N; Fujita N; Yoshimori T; Hayashi N
    Int J Cancer; 2012 Aug; 131(3):548-57. PubMed ID: 21858812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression.
    Takeuchi A; Shiota M; Tatsugami K; Yokomizo A; Eto M; Inokuchi J; Kuroiwa K; Kiyoshima K; Naito S
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1557-64. PubMed ID: 21544629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib.
    Kang HC; Tan KS; Keefe SM; Heitjan DF; Siegelman ES; Flaherty KT; O'Dwyer PJ; Rosen MA
    AJR Am J Roentgenol; 2013 Jan; 200(1):120-6. PubMed ID: 23255750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
    Tamaskar I; Garcia JA; Elson P; Wood L; Mekhail T; Dreicer R; Rini BI; Bukowski RM
    J Urol; 2008 Jan; 179(1):81-6; discussion 86. PubMed ID: 17997441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.